ÃÑ 951ÆäÀÌÁö

496ÆäÀÌÁö º»¹®½ÃÀÛ

2014
³ó¸²Ãà»ê°Ë¿ª°Ë»ç±â¼ú°³¹ß»ç¾÷ ¿¬±¸°úÁ¦Á¦¾È¼­
6. Park J H. Requirements for improved vaccines against foot-and-mouth disease
epidemics. Clin Exp Vaccine Res 2013;2:8-18
7. Peter W.M., Alexandr V.S., Ilya F. Production and characterization of vaccines
based on flaviviruses defective in replication. 2006. 351:432-443
8. Sabena U, Jason H, Juan M. Pacheco, Luis L. Rodriguez, Elizabeth R. Safe
foot-and-mouth disease vaccine platform with two negative markers for
differentiating infected from vaccinated animals (diva). J Virol.
2012;86(21):11675-85.
9. Sutmoller,P . Barteling,S . S., OlascoagaR, . C., Sumption,K . J. Control and
eradication of foot-and-mouth disease. 2003. Virus Res. 91:101-144.
10. Tina k., Elizabeth R., Barry B., Gordon W., Peter W.M. Characterization of
Synthetic Foot-and-Mouth Disease Virus Provirions Separates Acid-Mediated
Disassembly from Infectivity. J. Virol. 1997, 71(4):2851
11. Uddowla S, Hollister J, Pacheco JM, Rodriguez LL, Rieder E. A safe foot-and-
mouth disease vaccine platform with two negative markers for differentiating
infected from vaccinated animals. J Virol 2012;86:11675-85.
12. Vallee, H., Cane, H., Rinjard, P. On immunisation against foot-and-mouth disease.
1925. Rech.Med. Vet. 101: 297-299.
13. Zibert A, Maass G, Strebel K, Falk MM, Beck E. Infectious foot-and-mouth
disease virus derived from a cloned full-length cDNA. J Virol. 1990;64(6):2467-73
8
³ó¸²Ãà»ê°Ë¿ªº»ºÎ

496ÆäÀÌÁö º»¹®³¡



ÇöÀç Æ÷Ä¿½ºÀÇ ¾Æ·¡³»¿ëµéÀº µ¿ÀÏÇÑ ÄÁÅÙÃ÷¸¦ °¡Áö°í ÆäÀÌÁö³Ñ±è È¿°ú¹× ½Ã°¢Àû È¿°ú¸¦ Á¦°øÇÏ´Â ÆäÀÌÁöÀ̹ǷΠ½ºÅ©¸°¸®´õ »ç¿ëÀÚ´Â ¿©±â±îÁö¸¸ ³¶µ¶ÇϽðí À§ÀÇ ÆäÀÌÁöÀ̵¿ ¸µÅ©¸¦ »ç¿ëÇÏ¿© ´ÙÀ½ÆäÀÌÁö·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
»ó´Ü¸Þ´º ¹Ù·Î°¡±â ´ÜÃàÅ°¾È³» : ÀÌÀüÆäÀÌÁö´Â ÁÂÃø¹æÇâÅ°, ´ÙÀ½ÆäÀÌÁö´Â ¿ìÃø¹æÇâÅ°, ùÆäÀÌÁö´Â »ó´Ü¹æÇâÅ°, ¸¶Áö¸·ÆäÀÌÁö´Â ÇϴܹæÇâÅ°, ÁÂÃøÈ®´ëÃà¼Ò´Â insertÅ°, ¿ìÃøÈ®´ëÃà¼Ò´Â deleteÅ°